0
Letters |

Mortality and Adherence to Pharmacotherapy After Acute Myocardial InfarctionMortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction

JAMA. 2007;297(17):1877-1878. doi:10.1001/jama.297.17.1877-a
Text Size: A A A
Published online

AUTHOR INFORMATION

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

MORTALITY AND ADHERENCE TO PHARMACOTHERAPY AFTER ACUTE MYOCARDIAL INFARCTION

To the Editor: In their study of adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction (AMI), Dr Rasmussen and colleagues1 suggest that the relationship between high adherence and lower mortality is due to an active drug effect rather than to a “healthy adherer” effect. Adherence to placebo has also been associated with lower mortality,2 suggesting that other factors may also be important. One of these factors may be depression, since depression is associated with poor adherence3 and with increased mortality after MI.3

If depression rather than drug effect were the causative agent, then the relationship of adherence to mortality should exist whether or not the drug is active. Rasmussen et al conclude that they are not observing a healthy adherer effect because high adherence to β-blockers and statins was associated with improved survival, whereas high adherence to calcium channel blockers (CCBs) was not. The authors use adherence to CCBs as a control since CCBs have no proven survival advantages after an MI. However, immediate-release nifedipine is contraindicated (class III) in the treatment of ST-elevation myocardial infarction (STEMI), and diltiazem and verapamil are contraindicated in STEMI with left ventricular systolic dysfunction and heart failure.4 In non-STEMI, immediate-release dihydropyridine CCBs are contraindicated (class III) in the absence of a β-blocker, and extended-release nondihydropyridine CCBs have a class IIb recommendation.5 If CCBs are harmful, the lack of a relationship between adherence and mortality could potentially represent the healthy adherer effect counterbalancing the harmful effect of CCBs.

Rasmussen et al do not report specifically on depression, but the patients in their study with low adherence had a significantly greater prevalence of psychiatric illness than those with high adherence.1 While depression is associated with poor adherence and both are associated with increased mortality, how depression and adherence may interact to influence mortality has not been studied. Adherence may mediate the relationship between depression and mortality. Alternatively, there may be an interaction such that patients with both depression and poor adherence have higher mortality than patients with either alone. An analysis that attempted to delineate the relationship between depression, adherence, and mortality would be of great interest, as it could inform clinicians and researchers where to focus their efforts to achieve the most benefit in the treatment of depression, improvement of adherence, or both.

Financial Disclosures: None reported.

References
Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.  JAMA. 2007;297177-186
PubMed
Simpson SH, Eurich DT, Majumdar SR.  et al.  A meta-analysis of the association between adherence to drug therapy and mortality.  BMJ. 2006;33315-21
PubMed
Bush DE, Ziegelstein RC, Patel UV.  et al.  Post-myocardial infarction depression.  Evid Rep Technol Assess (Summ). 2005;1231-8
PubMed
Antman EM, Anbe DT, Armstrong PW.  et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).  Circulation. 2004;110588-636
PubMed
Braunwald E, Antman EM, Beasley JW.  et al.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).  J Am Coll Cardiol. 2000;36970-1062
PubMed

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.  JAMA. 2007;297177-186
PubMed
Simpson SH, Eurich DT, Majumdar SR.  et al.  A meta-analysis of the association between adherence to drug therapy and mortality.  BMJ. 2006;33315-21
PubMed
Bush DE, Ziegelstein RC, Patel UV.  et al.  Post-myocardial infarction depression.  Evid Rep Technol Assess (Summ). 2005;1231-8
PubMed
Antman EM, Anbe DT, Armstrong PW.  et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).  Circulation. 2004;110588-636
PubMed
Braunwald E, Antman EM, Beasley JW.  et al.  ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).  J Am Coll Cardiol. 2000;36970-1062
PubMed
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.